Logotype for Alphatec Holdings Inc

Alphatec (ATEC) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Alphatec Holdings Inc

Q4 2025 earnings summary

24 Feb, 2026

Executive summary

  • Achieved Q4 2025 revenue of $213 million, up 20% year-over-year, and full-year revenue of $764 million, a 25% increase, driven by increased surgical volume and surgeon adoption.

  • Adjusted EBITDA for Q4 was $33 million (up 61% year-over-year, 16% margin), and $93 million for the full year (12% margin), marking significant profit margin expansion.

  • Free cash flow turned positive for the first full year, with $8 million in Q4 and $3 million for 2025, an improvement of $131 million year-over-year.

  • Net new surgeon users grew 23% in Q4 and 20% for the year, supporting durable growth and continued leadership in lateral and deformity spine procedures.

  • Maintained leadership in spine-focused procedural innovation, launching new platforms and expanding the procedural ecosystem.

Financial highlights

  • Q4 revenue: $213 million (+20% year-over-year); surgical revenue $190 million (+21%), EOS revenue $23 million (+14%).

  • Full-year revenue: $764 million (+25% year-over-year); surgical revenue $687 million (+26%), EOS revenue $77 million (+15%).

  • Q4 non-GAAP gross margin: 71%; full-year non-GAAP gross margin: 70%.

  • Q4 Adjusted EBITDA: $33 million (16% margin); full-year Adjusted EBITDA: $93 million (12% margin).

  • Ended Q4 with $161 million in cash and $60 million undrawn credit, totaling $221 million in available liquidity.

Outlook and guidance

  • 2026 revenue guidance: $890 million (+17% year-over-year), with $805 million surgical and $85 million EOS revenue.

  • 2026 Adjusted EBITDA guidance raised to $134 million (15% margin), up from $130 million.

  • Expected 2026 free cash flow of at least $20 million, with continued investment in inventory and PP&E.

  • Gross margin expected to approach 71% by end of 2026; operating expenses to grow ~11% vs. 17% revenue growth, driving ~400 bps operating margin improvement.

  • Revenue growth algorithm driven by continued surgeon adoption and utilization, with existing surgeons supporting a significant portion of 2026 volume.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more